CAL
IMDX

Capital Advisors Ltd’s Insight Molecular Diagnostics IMDX Stock Holding History

Capital Advisors Ltd’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-61
Closed – – 1430
2023
Q3 		$0 Buy
+61
New +$227 ﹤0.01% 1419

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Advisors Ltd's IMDX Position: Q4 2023 in Review

Capital Advisors Ltd sold out of Insight Molecular Diagnostics (IMDX) in Q4 2023, closing a stake of 61 shares.

Capital Advisors Ltd first reported a position in IMDX in Q3 2023 and held it in 1 quarter. The position peaked at $0 in Q3 2023. 26 funds tracked by Wall St. Rank hold IMDX as of Q4 2023.

  • Capital Advisors Ltd reported no remaining Insight Molecular Diagnostics position as of Q4 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 61 Insight Molecular Diagnostics shares in Q4 2023.
  • Capital Advisors Ltd first reported a position in Insight Molecular Diagnostics in Q3 2023 and held it in 1 quarter.
  • Capital Advisors Ltd's Insight Molecular Diagnostics position peaked at $0 in Q3 2023.
  • 26 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2023.

Based on Capital Advisors Ltd's 13F filing for Q4 2023, filed 2 Feb 2024.